86-68-0

Basic information

• Product Name: QUININIC ACID
• Synonyms: 6-METHOXY-4-QUINOLINECARBOXYLIC ACID;6-METHOXYQUINOLINE-4-CARBOXYLIC ACID;QUININIC ACID;Cinchoninic Acid, 6-methoxy-;Nsc 403610
• CAS NO: 86-68-0
• Molecular Formula: C₁₁H₉NO₃
• Molecular Weight: 203.19
• EINECS: 237-014-3
• Product Categories: Fluorescent;Quinoline
• Mol File: 86-68-0.mol
• Article Data: 14

Chemical Properties

• Melting Point: 280°C (decompose)
• Boiling Point: 341.49°C (rough estimate)
• Flash Point: 186.9 °C
• Appearance: Pale yellow/crystals
• Density: 1.2621 (rough estimate)
• Vapor Pressure: 1.25E-06mmHg at 25°C
• Refractive Index: 1.4950 (estimate)
• Storage Temp.: 2-8°C
• Solubility: Solubility Slightly soluble in water, cold ethanol, ether
• PKA: 5.53(at 25℃)
• Merck: 14,8062
• CAS DataBase Reference: QUININIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: QUININIC ACID(86-68-0)
• EPA Substance Registry System: QUININIC ACID(86-68-0)

Safety Data

• Hazardous Substances Data: 86-68-0(Hazardous Substances Data)

Usage

Description

6-Methoxy-4-quinolinecarboxylic Acid is a derivative of 4-quinolinecarboxylic acids, which is a potential antitumor (such as leukemia) and antiviral agent. It also has the potential to be used as immunosuppressive reagent as well as for the treatment of skin and epithelial diseases.

Sources

https://www.sigmaaldrich.com/catalog/product/aldrich/174823?lang=en®ion=US https://link.springer.com/article/10.1007/s11094-009-0187-1 https://patents.google.com/patent/US5084462A/en https://patents.google.com/patent/US4861783A/en

Uses

6-methoxyquinoline-4-carboxylic Acid is used in the preparation of tetrahydroisoquinoline amides as multidrug resistance reversers.

InChI:InChI=1/C11H9NO3/c1-15-7-2-3-10-9(6-7)8(11(13)14)4-5-12-10/h2-6H,1H3,(H,13,14)

Upstream product

• 6443-89-6 6-methoxyquinoline-4-carbonitrile 
• 84-55-9 viquidil 
• 7722-84-1 dihydrogen peroxide 
• 1435-55-8 dihydroquinidine 
• 39755-95-8 5-methoxyisatine 
• 858276-95-6 2-iodo-6-methoxy-quinoline-4-carboxylic acid 
• 50-54-4 quinine sulfate 
• 250641-13-5 6-methoxyquinoline-2,4-dicarboxylic acid 
• 113-24-6 sodium pyruvate 
• 67-63-0 isopropyl alcohol 
• 84-31-1 6'-methoxycinchonidone 
• 104-94-9 4-methoxy-aniline 
• 857622-89-0 N-(4-methoxy-phenyl)-N-methyl-2-oxo-succinamic acid ethyl ester 
• 66695-42-9 ethyl 6-methoxy-1-methyl-2-oxo-1,2-dihydroquinoline-4-carboxylate 

Downstream Products

• 19834-77-6 methyl 6-methoxyquinoline-4-carboxylate 
• 6279-51-2 6-methoxy-4-aminoquinoline 
• 859780-30-6 6-hydroxy-quinoline-4-carbonyl chloride 
• 31610-09-0 Xanthochininsaeure-ethylester 
• 525-39-3 6-ethoxy-quinoline-4-carboxylic acid 
• 534-07-6 1,3-Dichloroacetone 
• 314741-44-1 [R]-2-(6-methoxyquinolin-4-yl)oxirane 
• 92288-15-8 (6-methoxyquinolin-4-yl)methanol 
• 5345-57-3 6-methoxyquinoline-4-carboxylic acid ethyl ester 
• 74-87-3 methylene chloride 
• 4312-44-1 6-hydroxyquinoline-4-carboxylic acid 

Relevant articles and documents

6,7-Dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline amides and corresponding ester isosteres as multidrug resistance reversers

Aiming to deepen the structure–activity relationships of the two P-glycoprotein (P-gp) modulators elacridar and tariquidar, a new series of amide and ester derivatives carrying a 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline scaffold linked to different methoxy-substituted aryl moieties were synthesised. The obtained compounds were evaluated for their P-gp interaction profile and selectivity towards the two other ABC transporters, multidrug-resistance-associated protein-1 and breast cancer resistance protein, showing to be very active and selective versus P-gp. Two amide derivatives, displaying the best P-gp activity, were tested in co-administration with the antineoplastic drug doxorubicin in different cancer cell lines, showing a significant sensitising activity towards doxorubicin. The investigation on the chemical stability of the derivatives towards spontaneous or enzymatic hydrolysis, showed that amides are stable in both models while some ester compounds were hydrolysed in human plasma. This study allowed us to identify two chemosensitizers that behave as non-transported substrates and are characterised by different selectivity profiles.

NOVEL FAP INHIBITORS

The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.

NOVEL FAP INHIBITORS

The present invention relates to novel inhibitors having high selectivity and specificity for FAP (fibroblast activation protein). Said inhibitors are useful as a human and/or veterinary medicine, in particular for the treatment and/or prevention of FAP-related disorders such as but not limited to proliferative disorders.